Input your canine patient’s weight in pounds below to calculate their rehydration rate. Review what physical exam symptoms are present at each stage of dehydration.
681.8
mLs OF FLUID TO MAINTAIN OVER 24 HOURS
568.2
mLs AT 5% DEHYDRATION
795.5
mLs AT 7% DEHYDRATION
1,136.4
mLs AT 10% DEHYDRATION
1,363.6
mLs AT 12% DEHYDRATION
1,418
mLs OF FLUID TO MAINTAIN OVER 24 HOURS
1,182
mLs AT 5% DEHYDRATION
1,655
mLs AT 7% DEHYDRATION
2,364
mLs AT 10% DEHYDRATION
2,836
mLs AT 12% DEHYDRATION
25
PHYSICAL EXAM FINDINGS
Tacky mucous membranes
Decreased skin turgor and dry mucous membranes
Skin tenting persistent, prolonged capillary refill time, dry mucous membranes, and sunken eyes
Signs of shock present and death is possible if not corrected
Physical exam findings at each stage of dehydration
5%
Tacky mucous membranes
7%
Decreased skin turgor and dry mucous membranes
10%
Skin tenting persistent, prolonged capillary refill time, dry mucous membranes, and sunken eyes
12%
Signs of shock present and death is possible if not corrected
Dehydration is one of the most common clinical signs of gastrointestinal disease. Providing intravenous fluids (IV) is a common way to treat dehydration and account for continued fluid losses. When used appropriately, IV fluids can improve outcomes for these patients.
To support the veterinarian in the clinic, we have added a tool to help calculate the dehydration fluid rate for the canine patient. This tool is meant to aid in efficiency and provide support to the veterinary professional. Any time IV fluid therapy is given, please evaluate the individual patient’s disease process and individual needs. The calculation above considers a 60 mL/kg/day maintenance rate and using crystalloid fluids.
Next, calculate to determine the hourly rate.
Input the level of dehydration and the number of hours needed for rehydration plus continued loses in mLs to calculate hourly rate.
(
681.8÷ 24 HOURS
)÷ 24 hours ) + (
+
(
1,182AT 5%
AT 5%
AT 7%
AT 10%
AT 12%
÷
8HOURS
) =
TOTAL HOURLY RATE:
91.92+CONTINUED LOSSES IN mLs
Please check to see that the calculated results are appropriate and use these at your own risk. Patients with certain health conditions (e.g. cardiac dysfunction, renal disease, hepatic disease, etc.) may require adjustment of dosage amount and/or frequency of administration of certain drugs; please see the drug monograph or drug insert for further information on adjusting dosages. Dosages should be confirmed prior to dispensing medications unfamiliar to you.
In addition to dehydration, other common
signs of pancreatitis include¹:
Vomiting
CRANIAL
ABDOMINAL PAIN
DECREASED
APPETITE
DECREASED
ACTIVITY
FECES CONSISTENCY
& FECAL BLOOD
Introducing PANOQUELL®-CA1
The first FDA conditionally approved innovative solution for the management of clinical signs associated with acute onset of pancreatitis in dogs.
Effectiveness
Based on the data submitted by the sponsor for the conditional approval of PANOQUELL®-CA1, FDA determined that the drug is safe and has a reasonable expectation of effectiveness when used according to the labeling. The effectiveness of fuzapladib sodium was demonstrated in a well-controlled pilot field study. Dogs treated with fuzapladib sodium had a statistically significant reduction in MCAI scores compared to control.
Safety
In the pilot field effectiveness study, PANOQUELL®-CA1 was administered safely with other supportive care treatments including anti-emetics and pain control. The most common adverse reactions included anorexia, digestive tract disorders, respiratory tract disorders, and hepatopathy and jaundice.
In a good laboratory practice, pivotal target animal safety study, the administration of PANOQUELL®-CA1 as an IV injection once daily for nine days at doses of 0, 0.4, 1.2, and 2 mg/kg fuzapladib sodium did not produce systemic toxicity and had an acceptable margin of safety. The administration of PANOQUELL®-CA1 resulted in swelling and bruising at the injection site, with associated gross pathology and histopathological findings, hypertension, and mild thrombocytopenia. This nine-day safety study supports the safe use of PANOQUELL®-CA1 when administered IV to dogs, according to the label.3
Cost Effective
PANOQUELL®-CA1 is cost effective. The multi-use vial treats multiple patients, thus reducing waste.
¹Keany, KM, Fosgate, GT, Perry, SM, Stroup, ST, Steiner, JM. Serum concentrations of canine pancreatic lipase immunoreactivity and C-reactive protein for monitoring disease progression in dogs with acute pancreatitis. J Vet Intern Med. 2021; 35( 5): 2187- 2195. https://doi.org/10.1111/jvim.16218
²Cridge, H, Lim, SY, Algül, H, Steiner, JM. New insights into the etiology, risk factors, and pathogenesis of pancreatitis in dogs: Potential impacts on clinical practice. J Vet Intern Med. 2022; 36( 3): 847- 864. doi:10.1111/jvim.16437
³Refer to product insert for more information
